The characteristics and clinical course of patients with melioidosis and cancer
Tej Shukla,Simon Smith,Kristoffer Johnstone,Patrick Donald,Josh Hanson
DOI: https://doi.org/10.1371/journal.pntd.0012631
2024-10-26
PLoS Neglected Tropical Diseases
Abstract:Patients with an active cancer are more likely to develop melioidosis, but the characteristics and clinical course of melioidosis in patients with cancer have not been examined in detail. Trimethoprim/sulfamethoxazole (TMP-SMX) prophylaxis is prescribed to prevent melioidosis in patients receiving immune suppressing anti-cancer therapy in some jurisdictions–and is recommended in national Australian guidelines–however the risks and benefits of this strategy are incompletely defined. The study took place in Far North Queensland (FNQ) in tropical Australia. The characteristics and clinical course of patients with melioidosis diagnosed in the FNQ region between January 1, 1998, and June 1, 2023, who had–and did not have–an active cancer were compared. We also determined the subsequent incidence of melioidosis in patients receiving immune suppressing anti-cancer therapy in the FNQ region between January 1, 2008, and June 1, 2023, who did–and did not–receive TMP-SMX chemoprophylaxis for Pneumocystis jirovecii infection. An active cancer was present in 47/446 (11%) cases of melioidosis diagnosed between January 1, 1998, and June 1, 2023; there was no association between melioidosis and any cancer type. Patients with melioidosis and cancer were more likely to be older (odds ratio (OR) (95% confidence interval (CI): 1.05 (1.03–1.08) P<0.0001) and immunosuppressed (OR (95% CI): 11.54 (5.41–24.6), p<0.0001) than patients without cancer. Immune suppressing anti-cancer therapy had been prescribed to 17/47 (36%) in the 12 months prior to their diagnosis of melioidosis. Only 10/47 (21%) with cancer and melioidosis in the cohort had received no immune suppressing anti-cancer therapy and had no other risk factors for melioidosis. Twelve months after the diagnosis of melioidosis, 25/47 (53%) were still alive; 9/22 (41%) deaths were due to melioidosis and 13/22 (59%) were due to the underlying cancer. Between 2008 and June 2023, there were 4400 individuals who received myelosuppressive anti-cancer therapy in the FNQ region. There was no significant difference in the incidence of melioidosis between patients who did–and did not–receive TMP-SMX chemoprophylaxis with their myelosuppressive anti-cancer therapy (1/737 (0.15%) versus 16/3663 (0.44%); relative risk (95% confidence interval): 0.31 (0.04–2.34), p = 0.20) and no significant difference in the incidence of fatal melioidosis (0/737 versus 3/3663 (0.08%), p = 0.58). Patients with cancer are predisposed to developing melioidosis and immune suppressing anti-cancer therapy increases this risk further. However, in this region of Australia, there was no significant difference in the subsequent development of melioidosis in patients who did–and did not–receive TMP-SMX chemoprophylaxis during their myelosuppressive anti-cancer therapy. In this study from a tertiary hospital in tropical Australia, an active cancer was present in 11% of 446 patients with cultured-confirmed melioidosis, However, no solid organ or haematological cancer diagnosis appeared to be associated with developing the infection. Approximately half of the individuals with cancer who developed melioidosis died within 12 months of their melioidosis diagnosis, however, deaths were more commonly due to their underlying cancer than their melioidosis. Immune suppressing anti-cancer therapy had been prescribed in the prior 12 months in 36% of the individuals with cancer and melioidosis. Trimethoprim-sulfamethoxazole (TMP-SMX) is not prescribed routinely to prevent melioidosis in local patients receiving myelosuppressive anti-cancer therapy, but individuals receiving twice weekly TMP-SMX chemoprophylaxis against Pneumocystis jirovecii pneumonia did not have a statistically lower rate of melioidosis than individuals who did not receive this chemoprophylaxis. Melioidosis was a rare complication of myelosuppressive anti-cancer therapy in the region. Only 16/3663 (0.44%) individuals not receiving TMP-SMX chemoprophylaxis developed melioidosis, and only 3/3663 died from the disease (0.08%). As TMP-SMX has a range of potential side effects–and has the potential to interrupt the delivery of anti-cancer therapy and drive resistance to an important antibiotic–our data do not presently support TMP-SMX prophylaxis for melioidosis in patients receiving anti-cancer therapies in this region of Australia.
tropical medicine,parasitology